HRT Financial’s BridgeBio Pharma BBIO Stock Holding History

HRT Financial’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.34M	Buy	71,865 +30,766	+75%	+$2.23M	0.01%	951
2025 Q4	$3.14M	Sell	41,099 -20,202	-33%	-$1.33M	0.01%	1016
2025 Q3	$3.18M	Buy	+61,301	New	+$2.99M	0.01%	899
2024 Q2	–	Sell	-16,524	Closed	-$510K	–	2218
2024 Q1	$510K	Buy	+16,524	New	+$562K	﹤0.01%	1248
2023 Q4	–	Sell	-37,211	Closed	-$981K	–	2314
2023 Q3	$981K	Buy	+37,211	New	+$1.06M	0.01%	988
2023 Q2	–	Sell	-162,406	Closed	-$2.69M	–	2467
2023 Q1	$2.69M	Buy	162,406 +56,770	+54%	+$662K	0.03%	466
2022 Q4	$804K	Buy	105,636 +10,488	+11%	+$100K	0.01%	1090
2022 Q3	$945K	Buy	95,148 +77,921	+452%	+$810K	0.01%	973
2022 Q2	$156K	Buy	+17,227	New	+$144K	﹤0.01%	2324
2022 Q1	–	Sell	-53,138	Closed	-$886K	–	3098
2021 Q4	$886K	Sell	53,138 -191,518	-78%	-$8.1M	0.01%	1238
2021 Q3	$11.5M	Buy	+244,656	New	+$13.1M	0.07%	131

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's BBIO Position: Q1 2026 in Review

HRT Financial increased its BridgeBio Pharma (BBIO) stake by 75% in Q1 2026, buying an estimated $2.23M and bringing the position to 71,865 shares worth $5.34M. The position accounts for 0.01% of the portfolio, ranked #951.

HRT Financial first reported a position in BBIO in Q3 2021 and has held it in 11 quarters since. The position peaked at $11.5M in Q3 2021. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

HRT Financial held 71,865 shares of BridgeBio Pharma worth $5.34M as of Q1 2026.
HRT Financial bought 30,766 BridgeBio Pharma shares in Q1 2026, an estimated $2.23M.
BridgeBio Pharma made up 0.01% of HRT Financial's portfolio in Q1 2026, its #951 holding.
HRT Financial first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 11 quarters since.
HRT Financial's BridgeBio Pharma position peaked at $11.5M in Q3 2021.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.